Patent details

93015 Product Name: "Carfilzomib eventuellement sous forme d'un sel pharmaceutiquement acceptable"

Basic Information

Publication number:
93015
Type:
SPC
SPC Type:
Medical
Basic Patent Number:
EP057844847
Legal Status:
Inactive
Application number:
93015
First applicant's nationality:
Procedural language:
French

Marketing Authorization

Marketing Authorization Number:
EU/1/15/1060 - Kyprolis -carfilzomib
Marketing Authorization Type:
Marketing Authorization Date:
23/11/2015
Marketing Authorization Status:
Accepted
Marketing Authorization Country:

Dates

Filing date:
06/04/2016
First Marketing Authorization date:
23/11/2015
Grant date:
06/06/2016
Activation date:
Publication date:
06/06/2016
Lapsed date:
Expiration date:
Renunciation date:
Revocation date:
Annulment date:
Basic SPC Expiration:
08/08/2030
SPC Extension Expiration:
08/08/2030
Rejection date:
Withdrawal date:

Owner

From:
20/04/2016
 
 

Name:
ONYX THERAPEUTICS, INC.
Address:
249 E. GRAND AVENUE, SOUTH SAN FRANCISCO, CA 94080, United States (US)

History of Owners

From:
06/04/2016
To:
19/04/2016

Name:
Onyx Therapeutics Inc.
Address:
c/o Onyx Pharmaceuticals, Inc. 2100 Powell Street, Emeryville, CA 94608, United States (US)

Agent

Name:
OFFICE FREYLINGER S.A.
From:
06/04/2016
Address:
Boîte Postale 48, L-8001, STRASSEN, Luxembourg (LU)
To:

Inventor

1

Name:
LAIDIG Guy, J.
Address:
United States (US)

2

Name:
SMYTH Mark, S.
Address:
United States (US)

Annual Fees

Annual Fee Due Date:
31/08/2025
Annual Fee Number:
21
Annual Fee Amount:
410 Euro
Expected Payer:
Last Annual Fee Payment Date:
Last Annual Fee Paid Number:
Payer:
Filing date Document type Number of pages